Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of cancers and inflammation, announces that it has progressed discussions with the
We were treated to a late RNS arrival yesterday from Omega (ODX), the specialist medical diagnostics company, as it noted concerns regarding the ability of certain lateral flow tests to
It would appear that there is something of a land grab going on for Tirupati Graphite (TGR), the specialist graphite producer.
Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells University of Auckland data
There was two for the price of one at pharma services group Open Orphan (ORPH), not only its hVIVO subsidiary signing a £5.7m contract with a specialist biotechnology company developing
Xtract Resources (XTR) continued its series of progress reports from its Bushranger copper-gold porphyry exploration project in New South Wales. Here the angled holes BRDD-21-013 and 014 of the Phase
Zak Mir takes a charting perspective on some of the most followed small caps on the UK market. Today’s selection includes Argo Blockchain, Cyanconnode, Corcel, Evgen, Bluejay, Deliveroo, Tower Resources,
Zak Mir takes a technical analysis look at some of the most followed small caps on the London market. Today’s selection includes Argo Blockchain, Goldplat, MySale, Cora Gold, Clontarf, e-Therapeutics,
Diagnostics continue to surf the rollercoaster of the pandemic / post-pandemic period, something which has been underlined by the latest update from Omega Diagnostics (ODX) on the occasion of the
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces preclinical data demonstrating that SFX-01 was effective in
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces further progress and an update on clinical trial plans for SFX-01 in glioblastoma (“GBM”).
